Optikusneuritis

 

 Permissions and Reprints

Zusammenfassung

Die Optikusneuritis ist eine häufige neuroophthalmologische Erkrankung, deren Diagnose meistens auf wenige Symptome und Befunde gestützt werden kann. Wichtig ist nicht nur die Abgrenzung zu anderen Sehnervenerkrankungen, sondern auch die Diagnose von Sonderformen, was häufig erst im Verlauf möglich ist. Diese Übersichtsarbeit will den aktuellen Stand hinsichtlich Diagnostik und Therapie aus der Sicht der Autoren wiedergeben.

Abstract

Optic neuritis is a frequent neuro-ophthalmological disease in which the diagnosis can be based on just a few symptoms and findings. It is not only important to differentiate from other optic nerve disorders but also to recognise special types of optic neuritis, which is mostly only possible during the course of the disease. This article presents a review of the current state in diagnosis and therapy from the authorsʼ personal point of view.

• Literatur

• 1 Beisse F, Beisse C, Lagreze WA et al. Aktuelle Empfehlungen zu Neuritis nervi optici. Ophthalmologe 2014; 111: 722-726
  PubMedGoogle Scholar
• 2 Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler 2014; 20: 520-526
  CrossrefPubMedGoogle Scholar
• 3 Miller DH, Fazekas F, Montalban X et al. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler 2014; 20: 527-536
  CrossrefPubMedGoogle Scholar
• 4 DGN/KKNMS Leitlinie zur Diagnose und Therapie der Multiplen Sklerose. 2012 Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/030-050l_S2e_Multiple_Sklerose_Diagnostik_Therapie_2014-06.pdf Stand: 14.08.2014
  PubMedGoogle Scholar
• 5 Trobe JD. The Neurology of Vision. Oxford: Oxford University Press; 2001
  Google Scholar
• 6 Davis FA, Bergen D, Schauf C et al. Movement phosphenes in optic neuritis: a new clinical sign. Neurology 1976; 26: 1100-1104
  CrossrefPubMedGoogle Scholar
• 7 Fraser CL, Davagnanam I, Radon M et al. The time course and phenotype of Uhthoff phenomenon following optic neuritis. Mult Scler 2011; 18: 1042-1044
  PubMedGoogle Scholar
• 8 Nevalainen J, Krapp E, Paetzold J et al. Visual field defects in acute optic neuritis–distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution. Graefes Arch Clin Exp Ophthalmol 2008; 246: 599-607
  CrossrefPubMedGoogle Scholar
• 9 Keltner JL, Johnson CA, Spurr JO et al. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1993; 111: 231-234
  CrossrefPubMedGoogle Scholar
• 10 Ong HS, Fraser C, Davagnanam I et al. Acute visual loss in papilloedema: the diagnostic pitfalls. Int Ophthalmol 2014; 34: 607-612
  CrossrefPubMedGoogle Scholar
• 11 Braun F, Wilhelm H. Farbvergleichstests bei einseitigen Optikusneuropathien. Klin Monatsbl Augenheilkd 2010; 227: 852-856
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Fernandes DB, Ramos Rde I, Falcochio C et al. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol 2012; 32: 102-106
  CrossrefPubMedGoogle Scholar
• 13 Beck RW, Cleary PA, Anderson jr. MM et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581-588
  CrossrefPubMedGoogle Scholar
• 14 Traisk F, Lindquist L. Optic nerve involvement in Lyme disease. Curr Opin Ophthalmol 2012; 23: 485-490
  CrossrefPubMedGoogle Scholar
• 15 Trauzettel-Klosinski S, Diener HC, Fahle M. Vergleich des Flimmertests nach Aulhorn mit den visuell evozierten Potentialen in der Diagnostik der Neuritis nervi optici. Fortschr Ophthalmol 1990; 87: 171-177
  PubMedGoogle Scholar
• 16 Batra M. Magnetresonanztomografie in der neuroophthalmologischen Diagnostik. Klin Monatsbl Augenheilkd 2011; 228: 957-962
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis: should MR criteria for dissemination in time be less stringent. Ann Neurol 2004; 55: 297
  PubMedGoogle Scholar
• 18 Group ONS. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727-732
  PubMedGoogle Scholar
• 19 Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840-846
  CrossrefPubMedGoogle Scholar
• 20 Polman CH, Koetsier JC, Wolters EC. Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. Clin Neurol Neurosurg 1985; 87: 187-192
  CrossrefPubMedGoogle Scholar
• 21 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
  CrossrefPubMedGoogle Scholar
• 22 Kieseier BC, Wiendl H. Transforming multiple sclerosis trials into practical reality. Lancet Neurol 2011; 10: 493-494
  CrossrefPubMedGoogle Scholar
• 23 Mealy MA, Wingerchuk DM, Greenberg BM et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69: 1176-1180
  PubMedGoogle Scholar
• 24 Marques IB, Matias F, Silva ED et al. Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 2013; 21: 583-586
  PubMedGoogle Scholar
• 25 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
  CrossrefPubMedGoogle Scholar
• 26 Oberwahrenbrock T, Schippling S, Ringelstein M et al. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012; 2012: 530305
  PubMedGoogle Scholar
• 27 Balk LJ, Killestein J, Polman CH et al. Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain 2012; 135: e226
  CrossrefPubMedGoogle Scholar
• 28 Gelfand JM, Nolan R, Schwartz DM et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012; 135: 1786-1793
  CrossrefPubMedGoogle Scholar
• 29 Petzold A. Microcystic macular oedema in MS: T2 lesion or black hole?. Lancet Neurol 2012; 11: 933-934
  CrossrefPubMedGoogle Scholar
• 30 Saidha S, Sotirchos ES, Ibrahim MA et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012; 11: 963-972
  CrossrefPubMedGoogle Scholar
• 31 Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415
  CrossrefPubMedGoogle Scholar
• 32 Thoo S, Cugati S, Lee A et al. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Mult Scler DOI: 10.1177/1352458514528759. Epub April 2, 2014
  PubMedGoogle Scholar
• 33 Trobe JD, Beck RW, Moke PS et al. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol 1996; 121: 547-553
  CrossrefPubMedGoogle Scholar
• 34 van Rijn LJ, Wilhelm H, Emesz M et al. Relation between perceived driving disability and scores of vision screening tests. Br J Ophthalmol 2002; 86: 1262-1264
  CrossrefPubMedGoogle Scholar
• 35 Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol 2008; 126: 994-995
  CrossrefPubMedGoogle Scholar
• 36 Morrow MJ, Wingerchuk D. Neuromyelitis optica. J Neuroophthalmol 2012; 32: 154-166
  CrossrefPubMedGoogle Scholar
• 37 Jarius S, Frederikson J, Waters P et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298: 158-162
  CrossrefPubMedGoogle Scholar
• 38 Merle H, Olindo S, Jeannin S et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012; 130: 858-862
  CrossrefPubMedGoogle Scholar
• 39 Kleiter I, Hellwig K, Berthele A et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239-245
  CrossrefPubMedGoogle Scholar
• 40 Wender M. Acute disseminated encephalomyelitis (ADEM). J Neuroimmunol 2011; 231: 92-99
  CrossrefPubMedGoogle Scholar
• 41 Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: review of the literature and new observations. J Neuroophthalmol 2011; 31: 58-68
  CrossrefPubMedGoogle Scholar
• 42 Sundaram SV, Purvin VA, Kawasaki A. Recurrent idiopathic neuroretinitis: natural history and effect of treatment. Clin Experiment Ophthalmol 2010; 38: 591-596
  CrossrefPubMedGoogle Scholar
• 43 Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2013; 261: 17-26
  PubMedGoogle Scholar
• 44 Beck RW. The optic neuritis treatment trial. Implications for clinical practice. Optic Neuritis Study Group. Arch Ophthalmol 1992; 110: 331-332
  CrossrefPubMedGoogle Scholar
• 45 Schmidt J, Gold R, Schonrock L et al. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000; 123: 1431-1441
  CrossrefPubMedGoogle Scholar
• 46 Garcia-Segura LM, Balthazart J. Steroids and neuroprotection: New advances. Front Neuroendocrinol 2009; 30: v-ix
  CrossrefPubMedGoogle Scholar
• 47 Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001; 117: 1-8
  CrossrefPubMedGoogle Scholar
• 48 Trobe JD, Sieving PC, Guire KE. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology 1999; 106: 2047-2053
  CrossrefPubMedGoogle Scholar
• 49 Zivadinov R, Rudick RA, De Masi R et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-1247
  CrossrefPubMedGoogle Scholar
• 50 Zivadinov R, Zorzon M, De Masi R et al. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci 2008; 267: 28-35
  CrossrefPubMedGoogle Scholar
• 51 Diem R, Hobom M, Maier K et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003; 23: 6993-7000
  PubMedGoogle Scholar
• 52 Dimitriu C, Bach M, Lagreze WA et al. Methylprednisolone fails to preserve retinal ganglion cells and visual function after ocular ischemia in rats. Invest Ophthalmol Vis Sci 2008; 49: 5003-5007
  CrossrefPubMedGoogle Scholar
• 53 Sellebjerg F, Nielsen HS, Frederiksen JL et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479-1484
  CrossrefPubMedGoogle Scholar
• 54 Burton JM, OʼConnor PW, Hohol M et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009; CD006921
  PubMedGoogle Scholar
• 55 Schilling S, Linker RA, König FB et al. Plasmaaustausch bei steroidresistenten Multiple-Sklerose-Schüben: Klinische Erfahrungen an 16 Patienten. Nervenarzt 2006; 77: 430-438
  CrossrefPubMedGoogle Scholar
• 56 Beck RW, Trobe JD, Moke PS et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121: 944-949
  CrossrefPubMedGoogle Scholar
• 57 Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904
  CrossrefPubMedGoogle Scholar
• 58 Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J Neuroophthalmol 2001; 21: 292-295
  CrossrefPubMedGoogle Scholar
• 59 Kinkel RP, Dontchev M, Kollman C et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012; 69: 183-190
  CrossrefPubMedGoogle Scholar
• 60 Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249
  CrossrefPubMedGoogle Scholar
• 61 Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582
  CrossrefPubMedGoogle Scholar
• 62 Comi G, Martinelli V, Rodegher M et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511
  CrossrefPubMedGoogle Scholar
• 63 Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008; 71 (Suppl. 03) S3-S7
  PubMedGoogle Scholar
• 64 OʼConnor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900
  CrossrefPubMedGoogle Scholar
• 65 OʼConnor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303
  CrossrefPubMedGoogle Scholar
• 66 Gold R, Kappos L, Arnold DL et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107
  CrossrefPubMedGoogle Scholar
• 67 Sühs K-W, Hein K, Sättler MB et al. A randomized, double-blind, phase II study on erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199-210
  CrossrefPubMedGoogle Scholar
• 68 Tsakiri A, Kallenbach K, Fuglo D et al. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012; 18: 72-81
  CrossrefPubMedGoogle Scholar
• 69 Rudick RA, Mi S, Sandrock jr. AW. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 2008; 8: 1561-1570
  CrossrefPubMedGoogle Scholar